Neurosurgical Oncology Ward 2

The Neurosurgical Oncology Ward 2 operates as a specialized division dedicated to the intricate management of complex skull base tumors. This encompasses a range of challenging intracranial neoplasms, including but not limited to, pituitary adenomas, craniopharyngiomas, skull base meningiomas, acoustic neuromas, trigeminal nerve sheath tumors, and jugular foramen tumors. Emphasizing primarily surgical treatments for pituitary adenomas, tailored surgical approaches for large invasive pituitary tumors, and facial nerve function and hearing preservation techniques for acoustic neuromas, this department exhibits an unparalleled domestic proficiency. Their pioneering work in the surgical treatment of brain metastases and comprehensive treatments based on molecular pathology are noteworthy. This division is endowed with the most advanced technologies in neurosurgery, encompassing neuronal navigation, neuroendoscopy, intraoperative electrophysiological monitoring, intraoperative fluorescence-guided surgery, and modern endocrine therapies. They demonstrate a comprehensive arsenal for the management of complex skull base conditions. With nearly a thousand diverse brain tumor surgeries performed annually, their therapeutic outcomes have achieved international renown, setting a benchmark within the nation.

Given the considerable complexity and high risk associated with the treatment of skull base tumors, the realm of skull base surgery is often hailed as the jewel in the crown of neurosurgery. The Tiantan Hospital's specialization in skull base tumors is a testament to unwavering tenacity and ceaseless exploration. Over the years, the department has amassed vast expertise and has been instrumental in nurturing some of the nation's most eminent skull base surgical teams.

Leading the discipline is Professor Wang Jia, a Doctor of Medicine, Chief Physician, Professor, and Doctoral Supervisor. Professor Jia has participated in exchange programs as a visiting scholar at the Barrow Neurological Institute in Phoenix, Arizona, USA in 2009, and the Surgical Oncology Research Institute at Cardiff University in the UK in 2013. He possesses an immense wealth of clinical experience in the diagnosis and surgical treatment of various neurological tumors. In particular, his expertise in the microsurgical treatment of skull base tumors (pituitary adenomas, craniopharyngiomas, acoustic neuromas, jugular foramen tumors) and minimally invasive treatment of brain metastases are internationally renowned. As the project leader, Professor Jia is deeply engaged in the fundamental research, clinical diagnosis and treatment, and precision technology research and development for common brain tumors. He has published 51 SCI articles in international journals as the first or corresponding author, with a cumulative impact factor of 243. He has secured approval for 9 national and provincial-level projects and is currently undertaking 6 research projects. Professor Jia holds esteemed positions such as the Vice President of the Neurosurgery Branch of the Chinese Medical Association, President of the Neurosurgery Branch of the Chinese Equipment Association, Deputy Chairman of the Neurosurgery Branch of the Beijing Medical Association, Head of the Skull Base Surgery Group of the Neurosurgery Branch of the Beijing Medical Association, and Chief Editor of the "Chinese Journal of Neurosurgery".

Professor Guijun Jia, a Chief Physician and Doctoral Supervisor, has been engaged in neurosurgery clinical work for 30 years. He has served as the Director of the Skull Base Tumor Ward for many years and possesses deep expertise in the surgical treatment of skull base tumors, earning widespread acclaim from both domestic and international colleagues, as well as patients. He has led or participated in projects like the Beijing Natural Fund, the National 863 Plan "Research on the Protein Molecular Network of Pituitary Adenomas Based on Clinical Information", and research related to the molecular pathology of brain tumors, a public welfare industry scientific research project. He has been honored with multiple awards, including the 2006 Beijing Science and Technology Progress Award, the 2006 Chinese Medical Science and Technology Award, and the 2014 Chinese Medical Science and Technology Award.

Professor Deling Li, a Doctor of Medicine, Chief Physician, Professor, and Doctoral Supervisor, is a visiting scholar at Stanford University. He is the Deputy Director of the Neurosurgery Center at Beijing Tiantan Hospital, affiliated with the Capital Medical University, and the Deputy Director of Tumor Ward 2. He is a recipient of the National Natural Science Foundation's Excellent Young Fund, a Young Beijing Scholar, a young top talent of the Beijing Municipal Committee Organization Department, a Beijing Science and Technology Nova, and a laureate of the third "National Famous Doctors - Young and Promising" award. He also serves as the Deputy Director of the Youth Committee of the Neurosurgery Branch of the Chinese Medical Association. He has presided over 3 National Natural Science Foundation projects, 1 national key R&D project, and 7 provincial and ministerial level research projects. He has published 16 papers in international authoritative journals such as Science and Theranostics as the first or corresponding author, with his achievements being highly rated and cited by Lancet's sub-journals. He excels in the precise removal of pituitary adenomas, acoustic neuromas, brain metastases, and skull base tumors using various new technologies and is adept at the diagnosis and treatment of brain gliomas, lymphomas, and others.

In clinical diagnostics and treatment, we apply a comprehensive range of state-of-the-art techniques including advanced and practical microsurgical methods, neuroendoscopy, neuronavigation, multimodal image fusion, intraoperative neurophysiological monitoring, and artificial intelligence. Our minimal invasive treatment approach strives to completely remove the pathological tissue while maximally preserving the patient's neurological functions. As an example, in the area of acoustic neuroma, our team has utilized intraoperative electrophysiological monitoring technology to improve facial nerve preservation rate to 70-80%, achieving domestic leadership and first-class international standards.Moreover, our center pioneers innovative solutions for patients with deep-seated or functionally critical small brain metastases and gliomas. We were the first to implement domestically developed MRI-guided laser ablation, surpassing international technology constraints. Our parameters excel compared to similar international products, offering new treatment options for such patients.We also carry out fundamental research on flexible electrodes, collaborating with world-leading teams to develop stretchable high-density microarray electrodes. These conform closely to irregular regions such as the brainstem, proving their significant clinical translational value in accurately identifying vital brainstem nuclei, nerve tracts, and functional tumor boundaries. These research findings were published online in the journal Science on March 25, 2022. Our team's development of polymer flexible organic electrodes for continuous monitoring of cochlear nerves during acoustic neuroma surgery was also published in Nature Biomedical Engineering, a sub-journal of Nature.

In addition,Neurosurgical Oncology Ward 2 maintains a leading position in the following research areas:

1. Investigating the molecular mechanisms of different levels such as genes and proteins related to the invasiveness of pituitary adenomas.

2. Constructing a nationwide disease registration and research platform for real-world diagnosis and treatment, as well as standardized follow-up for pituitary adenomas and acoustic neuromas.

3. Advancing clinical transformation of research projects like electrophysiological monitoring technology and fluorescence-guided tumor resection.

4. Exploring applications of artificial intelligence and machine learning technologies in intelligent facial palsy grading, predicting effectiveness of pituitary adenoma drug treatments, and other areas.

5. Exploring strategies for molecular early warning and comprehensive treatment of brain metastatic cancer.

Neurosurgical Oncology Ward 2 The Neurosurgical Oncology Ward 2 operates as a specialized division dedicated to the intricate management of complex skull base tumors. This encompasses a range of challenging intracranial neoplasms, including but not limited to, pituitary adenomas, craniopharyngiomas, skull base meningiomas, acoustic neuromas, trigeminal nerve sheath tumors, and jugular foramen tumo…